What is the catalog number for Nutlin-3?

The catalog number for Nutlin-3 is HY-50696.

What sizes are available for Nutlin-3?

Nutlin-3 is available in the following size(s): 5 mg, 10 mM - 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg.

How many pack sizes does Nutlin-3 come in?

Nutlin-3 is available in 7 different pack sizes.

Is Nutlin-3 in stock?

Nutlin-3 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Nutlin-3?

Nutlin-3 is manufactured by QuantiMol.

What is the estimated delivery time for Nutlin-3?

Estimated delivery time for Nutlin-3 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Nutlin-3?

The safety data sheet for Nutlin-3 is available here: http://file.medchemexpress.com/batch_PDF/HY-50696/Nutlin-3-SDS-MedChemExpress.pdf.

Nutlin-3

Nutlin-3 is a commercial available p53-MDM2 inhibitor, with Ki of 90 nM.

Product Specifications

CAS Number

548472-68-0

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

E1/E2/E3 Enzyme; MDM-2/p53

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Nutlin-3.html

Purity

99.18

Solubility

DMSO : ≥ 50 mg/mL|Ethanol : 100 mg/mL (ultrasonic)

Smiles

O=C1NCCN(C(N2[C@@H](C3=CC=C(Cl)C=C3)[C@@H](C4=CC=C(Cl)C=C4)N=C2C5=CC=C(OC)C=C5OC(C)C)=O)C1

Molecular Formula

C30H30Cl2N4O4

Molecular Weight

581.49

Precautions

H315, H319, H335

References & Citations

[1]Yu Z, et al. Design, synthesis and biological evaluation of sulfamide and triazole benzodiazepines as novel p53-MDM2 inhibitors. Int J Mol Sci. 2014 Sep 5;15 (9) :15741-53.|[2]Zhang Y, et al. Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth.Cancer Biol Ther. Cancer Biol Ther. 2012 Aug;13 (10) :915-24.|[3]Supiot S, et al. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther. 2008 Apr;7 (4) :993-9.